Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

1(33%)

Results Posted

200%(2 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_2

67%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(1)

Detailed Status

Active, not recruiting1

Terminated1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (66.7%)

Phase 31 (33.3%)

Trials by Status

active_not_recruiting133%

terminated133%

completed133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

NCT05461170

terminatedphase_2

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567

completedphase_3

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011

Clinical Trials (3)

Showing 3 of 3 trials

NCT05461170Phase 2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Active Not Recruiting

NCT04454567Phase 2

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Terminated

NCT01363011Phase 3

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3